Lucarelli and colleagues in this issue of Journal of Diabetes Science and Technology describe the results of interference testing for a continuous glucose monitoring system. The authors follow the Clinical Laboratory Standards Institute guideline EP7-A2, including their conclusions, in which the concepts of a statistically significant interfering substance and a clinically important interference have been combined in a way whereby information from the experiment has been lost and could be misleading. A better way to treat the data is presented, including a simulation method to evaluate the effects of interferences.
